[1] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,29(2):98-122.[2] 张七一.临床合理用药指导手册心血管病分册[M].北京:人民卫生出版社,2007:6-6.[3] 李小鹰.慢性心力衰竭的治疗:从治疗指南到临床实践[J].中华内科杂志,2005,44(7):484-485[4] Fragasso G, Palloshi A, Puccetti P, et al.A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure [J]. J Am Coll Cardiol,2006,48(5):992-998.[5] Fotino A D, Thompson Paul A M, Bazzano L A. Effect of coenzyme Q10 supplementation on heart failure:a meta-analysis [J]. Am J Clin Nutr,2013,97(2):268-275.[6] Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration[J]. Am Heart J,2000,139(2 Pt 3):S120-S123.[7] Zhang L, Lu Y Z, Jiang H, et al.Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis[J]. J Am Coll Cardiol,2012,59(10):913-922.[8] 刘万里,黄鹤,王磊,等.曲美他嗪对慢性心力衰竭患者心率变异性影响的meta分析[J]. 临床误诊误治,2014,27(12):85-91.[9] 高德民.左卡尼丁治疗慢性充血性心力衰竭41例临床疗效观察[J]. 中国煤炭工业医学杂志,2013,16(1):39-40.[10] 许晓晗,张维君,周玉杰,等.曲美他嗪对PCI术相关心肌损伤及术后再发心绞痛症状的临床研究[J].首都医科大学学报,2012,33(4):42-46. |